These actions are driven through MHC class II antigen presentation, and we observed here that MHC class II-deficient, but not MHC class I-deficient mice, cannot eradicate the tumor, which is further indication of the involvement of the CD4+ rather than the CD8+ T-cell subset. This evidence concerns the gene CD8A and neoplasm.